Abstract | PURPOSE: METHODS: RESULTS: A progressive decrease in macular thickness and cystic changes was observed during the 2-month course of topical carbonic anhydrase inhibitor treatment, and best-corrected visual acuity improved from 20/100 to 20/50. Macular thickness remained stable after 6 months of follow-up. CONCLUSION:
|
Authors | Leandro C Zacharias, Remo Susanna Jr, Olof Sundin, Simone Finzi, Bianca N Susanna, Walter Y Takahashi |
Journal | Retinal cases & brief reports
(Retin Cases Brief Rep)
Vol. 9
Issue 1
Pg. 61-3
( 2015)
ISSN: 1937-1578 [Electronic] United States |
PMID | 25383852
(Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Carbonic Anhydrase Inhibitors
- MFRP protein, human
- Membrane Proteins
- Sulfonamides
- Thiophenes
- dorzolamide
|
Topics |
- Administration, Topical
- Carbonic Anhydrase Inhibitors
(administration & dosage)
- Female
- Frameshift Mutation
- Humans
- Macular Edema
(drug therapy)
- Membrane Proteins
(genetics)
- Microphthalmos
(drug therapy)
- Middle Aged
- Optic Disk Drusen
(drug therapy)
- Retinitis Pigmentosa
(drug therapy)
- Sulfonamides
(administration & dosage)
- Syndrome
- Thiophenes
(administration & dosage)
- Treatment Outcome
|